EMBC Stock Up 41% after 5-Day Win Streak
Embecta (EMBC) stock hit day 5 of a continuous streak of days with gains, with cumulative gains over this period amounting to a 41% return. The company has gained about $321 Mil in value over the last 5 days, with its current market capitalization at about $779 Mil. The stock remains 30.8% below its value at the end of 2024. This compares with year-to-date returns of 9.9% for the S&P 500.
EMBC provides diabetes care solutions, including pen needles, syringes, safety devices, and digital applications, serving wholesalers and distributors worldwide. After this rally, is EMBC still a buy – or is it time to lock in gains? Deep dive with Buy or Sell EMBC.
Comparing EMBC Stock Returns With The S&P 500
The following table summarizes the return for EMBC stock vs. the S&P 500 index over different periods, including the current streak:
- The Forces Behind PayPal’s 50% Stock Drop
- Is Boston Scientific’s Bull Thesis Still Intact?
- How Micron Stock Surges To $700
- AMD Stock Crash Is A Golden Money Making Opportunity
- This Strategy Pays You 12% While Lining Up STX at Bargain Prices
- The Next Big Rally in Micron Technology Stock Could Start Like This
| Return Period | EMBC | S&P 500 |
|---|---|---|
| 1D | 4.7% | 0.3% |
| 5D (Current Streak) | 41.2% | 1.9% |
| 1M (21D) | 45.5% | 3.6% |
| 3M (63D) | 13.0% | 9.9% |
| YTD 2025 | -30.8% | 9.9% |
| 2024 | 13.6% | 23.3% |
| 2023 | -23.1% | 24.2% |
| 2022 | -19.4% |
What is the point? Momentum often precedes conviction. A multi-day win streak can signal growing investor confidence or spark follow-on buying. Tracking such trends can help you ride the strength, or prepare for a well-timed entry if momentum fades. However, big gains can follow sharp reversals – but how has EMBC behaved after prior drops? See EMBC Dip Buyer Analysis to learn more.
Gains and Losses Streaks: S&P 500 Constituents
There are currently 114 S&P constituents with 3 days or more of consecutive gains and 11 constituents with 3 days or more of consecutive losses.
| Consecutive Days | # of Gainers | # of Losers |
|---|---|---|
| 3D | 49 | 2 |
| 4D | 33 | 5 |
| 5D | 20 | 3 |
| 6D | 5 | 0 |
| 7D or more | 7 | 1 |
| Total >=3 D | 114 | 11 |
Key Financials for Embecta (EMBC)
Last 2 Fiscal Years:
| Metric | FY2023 | FY2024 |
|---|---|---|
| Revenues | $1.1 Bil | $1.1 Bil |
| Operating Income | $322.3 Mil | $285.0 Mil |
| Net Income | $70.4 Mil | $78.3 Mil |
Last 2 Fiscal Quarters:
| Metric | 2025 FQ2 | 2025 FQ3 |
|---|---|---|
| Revenues | $259.0 Mil | $295.5 Mil |
| Operating Income | $73.7 Mil | $105.0 Mil |
| Net Income | $23.5 Mil | $45.5 Mil |
While EMBC stock looks attractive given its winning streak, investing in a single stock without detailed, thorough analysis can be risky. The Trefis High Quality (HQ) Portfolio, with a collection of 30 stocks, has a track record of comfortably outperforming its benchmark that includes all 3 – the S&P 500, S&P mid-cap, and Russell 2000 indices. Why is that? As a group, HQ Portfolio stocks provided better returns with less risk versus the benchmark index; less of a roller-coaster ride, as evident in HQ Portfolio performance metrics.